NCT02469896View on ClinicalTrials.gov

A Trial of Tocilizumab in ALS Subjects

PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

July 11, 2018

Study Completion Date

July 11, 2018

Conditions
ALSAmyotrophic Lateral SclerosisLou Gehrig's DiseaseMotor Neuron Disease
Interventions
DRUG

Tocilizumab

IV Infusion

OTHER

Placebo

IV Infusion

Trial Locations (5)

17033

Penn State College of Medicine Milton S. Hershey Medical Center, Hershey

27157

Wake Forest University School of Medicine, Winston-Salem

66160

University of Kansas Medical Center, Kansas City

85013

Barrow Neurological Institute, Phoenix

02114

Massachusetts General Hospital, Boston

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

ALS Association

OTHER

collaborator

Barrow Neurological Foundation

OTHER

collaborator

Massachusetts General Hospital

OTHER

collaborator

Genentech, Inc.

INDUSTRY

lead

Barrow Neurological Institute

OTHER

NCT02469896 - A Trial of Tocilizumab in ALS Subjects | Biotech Hunter | Biotech Hunter